Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25484597 | 1.00 | SIGMAR1 (0.46) | SIGMAR1EPHX1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL19142695 | 0.98 | SIGMAR1 (0.43) | SIGMAR1EPHX1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL19346264 | 0.93 | — | — | |
| SCHEMBL14378653 | 0.87 | — | — | |
| SCHEMBL18823623 | 0.85 | EPHX1 (0.55) | SIGMAR1EPHX1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL24022707 | 0.85 | EPHX1 (0.55) | SIGMAR1EPHX1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL25597375 | 0.76 | P2RX4 (0.36) | SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL18807454 | 0.75 | EPHX1 (0.50) | SIGMAR1EPHX1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL8336708 | 0.75 | EPHX1 (0.50) | SIGMAR1EPHX1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL16076630 | 0.74 | EPHX1 (0.43) | SIGMAR1EPHX1SMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205467-A1 | RAAV WITH CHEMICALLY MODIFIED CAPSID | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205467-A1 | RAAV WITH CHEMICALLY MODIFIED CAPSID | IGF2R, CFH, M6PR | SIGMAR1 2082/4885EPHX1 3370/4885SMN1; SMN2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.